Making its database and cloud services ‘AI-centric’ has brought Oracle newfound momentum. It still needs to figure out ...

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...